Lv1
20 积分 2021-08-09 加入
Gout
1天前
已完结
Gout
2天前
已完结
Immune and inflammatory mechanisms and therapeutic targets of gout: An update
2天前
已完结
Optimal treatment strategy for recurrent hepatocellular carcinoma based on recurrence time and tumor size: A propensity score matching study
4个月前
已完结
Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach
11个月前
已完结
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
11个月前
已完结
Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial
1年前
已完结
Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial
1年前
已完结
Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair–Deficient Colorectal Cancer
1年前
已完结
Current developments in gastric cancer: from molecular profiling to treatment strategy
1年前
已完结
皖公网安备34019202002308
